Methods: We therefore analyzed the 2-year clinical outcome data of 1033 complex TWENTE trial patients treated with second-generation everolimus-eluting Xience V or zotarolimus-eluting Resolute stents. The primary endpoint of the TWENTE trial, target vessel failure, was defined as cardiac death, target vessel-related myocardial infarction (MI), or target vessel revascularization (TVR).
Results: Among the 1033 complex patients, 529 (51.2%) were treated with Resolute stents and 504 (48.8%) with Xience V. Patient and procedure-related characteristics were similar between DES groups. After 2-year follow-up, clinical outcome was also similar between DES groups. In patients treated with Resolute and Xience V, TVF occurred in 12.1% and 12.3% of patients, respectively. In addition, DES groups did not differ in cardiac death, MI, or TVR, the individual components of TVF.
Conclusions: Complex patients treated with zotarolimus-eluting Resolute and everolimus-eluting Xience V stents showed similar safety and efficacy during 2-year follow-up.
|Journal||Journal of the American College of Cardiology|
|Issue number||18, Suppl. 1|
|Publication status||Published - 2013|
|Event||23rd Annual Scientific Symposium of Transcatheter Cardiovascular Therapeutics, TCT 2011 - San Francisco, United States|
Duration: 7 Nov 2011 → 11 Nov 2011
Conference number: 23